Verlmmune, a Washington, DC-based biotechnology company developing therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, raised USD2.5M in Seed funding.
The round was led by SeedFolio, with participation from Ulu Ventures, Proxima VC, NuFund Venture group, Gaingels, Mana Ventures, and others.
The company intends to use the funds to further accelerate its lead product development timelines as well as grow the team.
Led by CEO Joshua Wang and COO John Troyer, VerImmune is an early-stage biotechnology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors.
VerImmune was founded in early 2020 and had been headquartered for the past two years at Fastfoward 1812, near Johns Hopkins East Baltimore Campus in Maryland. In early 2022, the company moved its research and development laboratories to Johnson & Johnson Innovation – JLABS @ Washington, DC and is now fully operational. The relocation of VerImmune’s laboratory headquarters continues to be within the BioHealth Capital Region (BHCR) cluster which consists of Maryland, Washington D.C and Virginia.
FinSMEs
29/07/2022